inno shred glp-1 Shredβ’ π¨ Everyoneβs talking about GLP-1
Description
Eduard Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, AbbVie, Adamed, Alcediag, Angelini, Biogen, Beckley-Psytech, Biohaven, Boehringer-Ingelheim, Casen-Recordati, Celon Pharma, Clariane, Compass, Dainippon Sumitomo Pharma, Esteve, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Intra-Cellular therapies, Idorsia, Johnson & Johnson, Lundbeck, Luye Pharma, Medincell, Merck, Mitsubishi Tanabe Pharma, Newraxpharm, Newron, Novartis, Organon, Orion Corporation, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, Teva, and Viatris, outside the submitted work
In addition, first oral GLP-1 receptor agonist (oral semaglutide) was recently approved ( Table 1
These medications have demonstrated significant weight loss (5-22%) and metabolic benefits in rigorous clinical trials when prescribed and monitored by healthcare providers
doi: 10.1523/jneurosci.0529-11.2011
The bottom line GLP-1s and similar drugs are effective therapies for people with type 2 diabetes, overweight, and obesity
A dataset on formulation parameters and characteristics of drug-loaded PLGA microparticles
